Efegatran
Alternative Names: Efegatran sulfate; GYKI 14766; LY 294468Latest Information Update: 01 Aug 2002
At a glance
- Originator Eli Lilly and Company; IVAX Drug Research Institute
- Developer Eli Lilly and Company
- Class Anticoagulants; Antithrombotics; Oligopeptides; Small molecules
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronary thrombosis; Myocardial infarction; Thrombosis
Most Recent Events
- 11 Jan 2000 A study has been added to the Ischaemic Heart Disease and Thromboses therapeutic trials sections
- 26 Oct 1999 IVAX Corporation has acquired the Institute for Drug Research
- 11 Oct 1999 A study has been added to the adverse events, and Ischaemic Heart Disease and Thromboses pharmacodynamics and therapeutic trials sections